GEL-ONE
Seikagaku Corp. · Decision date Mar 22, 2011
What did the FDA approve?
FDA approved PMA P080020 for GEL-ONE on March 22, 2011. The applicant is Seikagaku Corp., and the product code is MOZ under the device category "Acid, hyaluronic, intraarticular." The stated indication is treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to non-pharmacologic therapy, NSAIDs, or analgesics such as acetaminophen.
The decision record is an original PMA approval, not a supplement or manufacturing notice. The source statement reports the approved indication only; it does not provide safety or effectiveness data, clinical trial details, or comparative performance information. No supplement type or supplement reason is listed.
FDA approval order statement
APPROVAL FOR THE GEL-ONE. THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO NON-PHARMACOLOGIC THERAPY, NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) OR ANALGESICS, E.G., ACETAMINOPHEN.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Mar 22, 2011
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P080020
- Regulatory pathway
- Premarket approval application
- Applicant
- Seikagaku Corp.
- Product code
- MOZ
- Decision code
- APPR
- Decision date
- Mar 22, 2011
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Acid, hyaluronic, intraarticular.
- Applicant
- Seikagaku Corp.
- Product code
- MOZ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P080020 received
Application receipt date recorded by FDA.
P080020 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P080020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P080020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
GEL-ONEP080020/S055 | Seikagaku Corp. | PMA supplement | Apr 9, 2026 | FDA |
GEL-ONEP080020/S057 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
Gel-OneP080020/S056 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
Explore the linked device profile
Other records with product code MOZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SUPARTZ FXP980044/S067 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
EUFLEXXA (1% sodium hyaluronate)P010029/S043 | Ferring Pharmaceuticals, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Orthovisc Injectable Intra-Articular DevicesP030019/S028 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
SUPARTZ FXP980044/S068 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
Gelsyn-3P110005/S015 | Ibsa Institut Biochimique SA | PMA supplement | Jul 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Seikagaku Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005
Sources and methodology
- Original FDA record: P080020
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


